2021 Fiscal Year Annual Research Report
| Project/Area Number |
20K17163
|
|---|
| Research Institution | Shonankamakura General Hospital (Center for Clinical and Translational Science) |
|---|
Principal Investigator |
サルベコウ アマンケルディ 医療法人沖縄徳洲会湘南鎌倉総合病院(臨床研究センター), 一般再生医療研究部, 主任部長 (80850776)
|
|---|
| Project Period (FY) |
2020-04-01 – 2022-03-31
|
| Keywords | 再生アソシエイト細胞 / エキソソーム / 心筋虚血再灌流障害 / angiomiRs / miRs |
|---|
| Outline of Annual Research Achievements |
Under vasculogenic conditioning, pro-inflammatory cell subsets of peripheral blood mononuclear cells (PBMCs) shift their phenotype to pro-regenerative cells such as vasculogenic endothelial progenitor cells, M2 macrophages, and regulatory T cells, collectively designated as regeneration-associated cells (RACs). In this study, we evaluated the therapeutic efficacy of RAC-derived extracellular vesicles (RACev) compared to mesenchymal stem cell-derived EVs (MSCev) in the context of myocardial ischemia reperfusion injury (M-IRI). RACev and MSCev were isolated via serial centrifugation and ultracentrifugation. EV quantity and size were characterized by nanoparticle tracking analysis.RACev markedly enhanced the viability, and proliferation of human umbilical vein endothelial cells in a dose-dependent manner compared to MSCev. Systemic injection of RACev improved cardiac fractional shortening, and protected from mitral regurgitation. RACev-transplanted group showed less interstitial fibrosis and enhanced capillary densities compared to the MSCev group. These beneficial effects were coupled with significant expression of angiogenesis, anti-fibrosis, anti-inflammatory, and cardiomyogenesis-related miRs in RACev. Overall, repetitive systemic transplantation of RACev is superior to MSCev in terms of cardiac function enhancements via crucial angiogenesis, anti-fibrosis, anti-inflammation miR delivery to the ischemic tissue.
The results published in peer reviewed journals and applied for international patent office.
|
Research Products
(7 results)
